OA11421A - An over-expressing homologous antigen vaccine and a method of making the same. - Google Patents

An over-expressing homologous antigen vaccine and a method of making the same. Download PDF

Info

Publication number
OA11421A
OA11421A OA1200000163A OA1200000163A OA11421A OA 11421 A OA11421 A OA 11421A OA 1200000163 A OA1200000163 A OA 1200000163A OA 1200000163 A OA1200000163 A OA 1200000163A OA 11421 A OA11421 A OA 11421A
Authority
OA
OAPI
Prior art keywords
gene
vaccine
attenuated
pathogen
organism
Prior art date
Application number
OA1200000163A
Other languages
English (en)
Inventor
Stephen M Boyle
Lynette Corbeil
Silvio Cravero
Gerhardt G Schurig
Nammalwar Srimaganathan
Ramesh Vemulapalli
Original Assignee
Virginia Tech Intell Prop
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PCT/US1997/023032 priority Critical patent/WO1999029340A1/en
Priority to AU57013/98A priority patent/AU759776C/en
Priority to BRPI9714904-7A priority patent/BR9714904B1/pt
Priority to NZ504993A priority patent/NZ504993A/xx
Priority to PT97953216T priority patent/PT1035863E/pt
Priority to CA002317806A priority patent/CA2317806A1/en
Priority to CNB971825173A priority patent/CN1321693C/zh
Priority to AT97953216T priority patent/ATE320264T1/de
Priority to US09/091,521 priority patent/US6149920A/en
Priority to ES97953216T priority patent/ES2259449T3/es
Priority to EP97953216A priority patent/EP1035863B1/de
Application filed by Virginia Tech Intell Prop filed Critical Virginia Tech Intell Prop
Priority to OA1200000163A priority patent/OA11421A/en
Priority to US09/692,623 priority patent/US6811787B1/en
Publication of OA11421A publication Critical patent/OA11421A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/23—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Brucella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
OA1200000163A 1997-12-05 2000-06-05 An over-expressing homologous antigen vaccine and a method of making the same. OA11421A (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CNB971825173A CN1321693C (zh) 1997-12-05 1997-12-05 一种过量表达的同源抗原疫苗及其制备方法
BRPI9714904-7A BR9714904B1 (pt) 1997-12-05 1997-12-05 vacina antìgena homóloga e microorganismo transgênico para a mesma.
NZ504993A NZ504993A (en) 1997-12-05 1997-12-05 A vaccine comprising a pathogen that over-expresses a homologous antigen
PT97953216T PT1035863E (pt) 1997-12-05 1997-12-05 Vacina de antigenio homologo sobre-expressante e um metodo para produzir a mesma
CA002317806A CA2317806A1 (en) 1997-12-05 1997-12-05 An over-expressing homologous antigen vaccine and a method of making the same
PCT/US1997/023032 WO1999029340A1 (en) 1997-12-05 1997-12-05 An over-expressing homologous antigen vaccine and a method of making the same
EP97953216A EP1035863B1 (de) 1997-12-05 1997-12-05 Ein impfstoff mit einem überexprimierenden homologen antigen sowie verfahren zu dessen herstellung
AT97953216T ATE320264T1 (de) 1997-12-05 1997-12-05 Ein impfstoff mit einem überexprimierenden homologen antigen sowie verfahren zu dessen herstellung
ES97953216T ES2259449T3 (es) 1997-12-05 1997-12-05 Vacuna de antigeno homologo sobreexpresado y procedimiento para la preparacion de la misma.
AU57013/98A AU759776C (en) 1997-12-05 1997-12-05 An over-expressing homologous antigen vaccine and a method of making the same
US09/091,521 US6149920A (en) 1997-12-05 1997-12-05 Over-expressing homologous antigen vaccine and a method of making the same
OA1200000163A OA11421A (en) 1997-12-05 2000-06-05 An over-expressing homologous antigen vaccine and a method of making the same.
US09/692,623 US6811787B1 (en) 1997-12-05 2000-10-20 Over-expressing homologous antigen vaccine and a method of making the same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US1997/023032 WO1999029340A1 (en) 1997-12-05 1997-12-05 An over-expressing homologous antigen vaccine and a method of making the same
CNB971825173A CN1321693C (zh) 1997-12-05 1997-12-05 一种过量表达的同源抗原疫苗及其制备方法
OA1200000163A OA11421A (en) 1997-12-05 2000-06-05 An over-expressing homologous antigen vaccine and a method of making the same.
US09/692,623 US6811787B1 (en) 1997-12-05 2000-10-20 Over-expressing homologous antigen vaccine and a method of making the same

Publications (1)

Publication Number Publication Date
OA11421A true OA11421A (en) 2004-04-21

Family

ID=39591168

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200000163A OA11421A (en) 1997-12-05 2000-06-05 An over-expressing homologous antigen vaccine and a method of making the same.

Country Status (12)

Country Link
US (2) US6149920A (de)
EP (1) EP1035863B1 (de)
CN (1) CN1321693C (de)
AT (1) ATE320264T1 (de)
AU (1) AU759776C (de)
BR (1) BR9714904B1 (de)
CA (1) CA2317806A1 (de)
ES (1) ES2259449T3 (de)
NZ (1) NZ504993A (de)
OA (1) OA11421A (de)
PT (1) PT1035863E (de)
WO (1) WO1999029340A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE320264T1 (de) 1997-12-05 2006-04-15 Virginia Tech Intell Prop Ein impfstoff mit einem überexprimierenden homologen antigen sowie verfahren zu dessen herstellung
CN1558773A (zh) * 2001-04-06 2004-12-29 巴斯德研究院 由与破伤风类毒素结合的霍乱弧菌o139的脂多糖的多糖部分组成的缀合疫苗
WO2004054508A2 (en) * 2002-12-12 2004-07-01 Walter Reed Army Institute Of Research Department Of The Army Immunogenic compositions including rough phenotype brucella host strains and complementation dna fragments
US7364745B2 (en) * 2004-02-06 2008-04-29 Virginia Tech Intellectual Properties, Inc. Development of a live, attenuated, recombinant vaccine for Brucellosis
WO2005084706A1 (en) * 2004-03-03 2005-09-15 Walter Reed Army Institute Of Research Mutant strains of brucella melitensis and immunogenic compositions
WO2007050099A2 (en) * 2004-12-01 2007-05-03 Aeras Global Tb Vaccine Foundation Recombinant bcg strains with attenuated immunosuppresive properties

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
US5468485A (en) * 1987-06-04 1995-11-21 Washington University Avirulent microbes and uses therefor
US6043057A (en) 1988-09-16 2000-03-28 Vitec Aktiebolag Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
ATE359370T1 (de) 1993-02-22 2007-05-15 Gen Hospital Corp Heterologe antigene in stämmen zur impfung mit lebendzellen
DE69434807T2 (de) * 1993-02-26 2007-03-29 Novozymes A/S Methode und system zur erhöhten produktion von kommerziell wichtigen exoproteinen in gram-positiven bakterien
CA2164298A1 (en) 1993-06-04 1994-12-22 Richard A. Young Stress proteins and uses therefor
US6036953A (en) 1996-11-29 2000-03-14 The General Hospital Corporation Heterologous antigens in live cell V. cholerae strains
WO1998046260A1 (en) * 1997-04-15 1998-10-22 Baylor College Of Medicine Pasteurella haemolytica vaccine
ATE320264T1 (de) * 1997-12-05 2006-04-15 Virginia Tech Intell Prop Ein impfstoff mit einem überexprimierenden homologen antigen sowie verfahren zu dessen herstellung

Also Published As

Publication number Publication date
WO1999029340A1 (en) 1999-06-17
EP1035863A4 (de) 2003-04-16
CN1321693C (zh) 2007-06-20
CA2317806A1 (en) 1999-06-17
US6149920A (en) 2000-11-21
CN1290173A (zh) 2001-04-04
PT1035863E (pt) 2006-07-31
BR9714904B1 (pt) 2010-07-13
EP1035863B1 (de) 2006-03-15
EP1035863A1 (de) 2000-09-20
US6811787B1 (en) 2004-11-02
AU759776B2 (en) 2003-05-01
NZ504993A (en) 2002-11-26
AU5701398A (en) 1999-06-28
ATE320264T1 (de) 2006-04-15
AU759776C (en) 2004-05-20
ES2259449T3 (es) 2006-10-01
BR9714904A (pt) 2001-11-27

Similar Documents

Publication Publication Date Title
US20080069843A1 (en) Salmonella vaccine
CA2292900A1 (en) Live attenuated vaccines
US20080254062A1 (en) Use of an avirulent bordetella mutant as a live vaccine vector
CA2429120C (en) Salmonella vaccine
Shimoji et al. Construction and vaccine potential of acapsular mutants of Erysipelothrix rhusiopathiae: use of excision of Tn 916 to inactivate a target gene
EP2121009A1 (de) Francisella-stamm für lebendvakzine
OA11421A (en) An over-expressing homologous antigen vaccine and a method of making the same.
JPH11514878A (ja) アクチノバシラス・プリゥロニュウモニエｒｔｘ毒素ａｐｘに対する免疫
US20030044431A1 (en) Over-expressing homologous antigen vaccine and a method of making the same
Pretorius et al. Protection against heartwater by DNA immunisation with four Ehrlichia ruminantium open reading frames
US5939075A (en) Mutants of Brucella melitensis
PL188925B1 (pl) Szczepionka przeciwko brucelozie, osłabiona lub awirulentna odmiana szczepu RB51 B. abortus, zastosowanie szczepionki, sposób wytwarzania szczepionki
US7332324B2 (en) Attenuated vaccine useful for immunizations against Coccidioides spp. infections
MXPA00005513A (en) An over-expressing homologous antigen vaccine and a method of making the same
World Health Organization The development of new/improved brucellosis vaccines: report of a WHO meeting, Geneva, Switzerland, 11-12 December 1997
KR101797276B1 (ko) 다중 돌연변이된 살모넬라 티피뮤리움 균주 및 이를 포함하는 식중독 예방 백신 조성물
World Health Organization The Development of new
EP0554335A1 (de) Corynebakterien und verwandte organismen als impfstoffvektoren